Research ArticleSpecial Section on Pharmacokinetics and ADME of Biological Therapeutics
Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper
Kathryn Ball, Gerard Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong-Yuan Yang and Hongbin Yu
Drug Metabolism and Disposition June 2022, 50 (6) 858-866; DOI: https://doi.org/10.1124/dmd.121.000463
Kathryn Ball
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Gerard Bruin
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Enrique Escandón
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Christoph Funk
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Joao N.S. Pereira
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Tong-Yuan Yang
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Hongbin Yu
Clinical Pharmacology & Quantitative Pharmacology, CPSS, R&D, AstraZeneca, Cambridge, United Kingdom (K.B.); Pharmacokinetic Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland (G.B.); PPDM ADME Biologics, Merck & Co., Inc., South San Francisco, California (E.E.); Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland (C.F.); Discovery & Development Technologies, Drug Disposition & Design, Merck Healthcare KGaA, Darmstadt, Germany (J.N.S.P.); Janssen BioTherapeutics, Janssen R&D, LLC, Spring House, Pennsylvania (T.-Y.Y.); and Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (H.Y.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleSpecial Section on Pharmacokinetics and ADME of Biological Therapeutics
PK and Biodistribution of Therapeutic Proteins
Kathryn Ball, Gerard Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong-Yuan Yang and Hongbin Yu
Drug Metabolism and Disposition June 1, 2022, 50 (6) 858-866; DOI: https://doi.org/10.1124/dmd.121.000463
Research ArticleSpecial Section on Pharmacokinetics and ADME of Biological Therapeutics
PK and Biodistribution of Therapeutic Proteins
Kathryn Ball, Gerard Bruin, Enrique Escandón, Christoph Funk, Joao N.S. Pereira, Tong-Yuan Yang and Hongbin Yu
Drug Metabolism and Disposition June 1, 2022, 50 (6) 858-866; DOI: https://doi.org/10.1124/dmd.121.000463
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement